High stone-free rate immediately after suctioning flexible ureteroscopy with Intelligent pressure-control in treating upper urinary tract calculi

Xingjian Gao†, Zedong Zhang†, Xinwei Li, Weiping Cai, Bin Zheng, Yijin Lu, Hualong Zhao, Junhong You, Gangfeng Zheng, Weilong Bao, Yutong Lai and Yisong Lv*

Abstract

Background: The retrospective observational study aimed to evaluate the safety and efficacy of suctioning flexible ureteroscopy with Intelligent pressure-control (SFUI) on treating upper urinary tract calculi in a large cohort.

Methods: Between July 2020 and August 2021, 278 patients with upper urinary tract calculi who underwent SFUI in our hospital were enrolled. Outcomes were stone-free rate (SFR) in one session and one-month after SFUI treatment, and complications scored by the Clavien-Dindo classification.

Results: A total of 310 kidneys underwent SFUI were included. The median surgery time was 75 min (ranged 60–110 min). One session and one-month SFRs were 80.65% and 82.26%, respectively. The one-session SFR was ≧ 87% in patients with Guy’s stone score of Grade I among stone size < 40 mm. Risk factors for unsuccessful stone-free in one session were stone history (adjusted odds ratio (aOR): 2.39, 95% confidence interval (CI): 1.21–4.73), stone size of 40–49 mm (aOR: 4.37, 95% CI: 1.16–16.45), Guy’s stone score ≧ Grade II (Grade II, aOR: 3.54, 95% CI: 1.18–10.59; Grade III, aOR: 10.95, 95% CI: 2.65–45.25). The incidence of Clavien-Dindo grade II-III complication was 3.26%. Complication is associated with Guy’s stone score III (aOR: 22.36, 95% CI: 1.81–276.36).

Conclusion: SFUI shows good safety and efficiency on treating upper urinary tract calculi. Patients with stone size < 40 mm or Guy’s stone score of Grade I have a high chance to reach stone-free after SFUI treatment.

Keywords: Suctioning flexible ureteroscopy with Intelligent pressure-control, Upper urinary tract stone, Stone-free rate, Guy’s stone score, Clavien-Dindo classification

Background

Upper urinary tract calculus is a common disease for global urologists. Both percutaneous nephrolithotomy (PCNL) and flexible ureteroscopy lithotripsy (FURL) are popular options for treating renal stones [1–4]. PCNL is recommended for kidney stone > 20 mm and FURL for < 20 mm in the guidelines issued by the American Urological Association [5]. FURL has high stone-free and low complication rates, however, it is easy to cause high renal pelvic pressure, resulting in complications including systemic inflammation and sepsis [6–8]. Recently, suctioning FURL has been revealed more suitable for patients with renal stones than the traditional one and acceptable in urological clinical practice [9, 10]. Besides, suctioning
flexible ureteroscopy with intelligent pressure-control (SFUI), one kind of the suction FURL, was reported to provide high lithotripsy efficacy and low complication rate in treating upper urinary tract calculi for patients with a solitary kidney [9]. This retrospective study aimed to evaluate the safety and efficacy of SFUI for treating upper urinary tract calculi in a large cohort.

**Methods**

**Patients**
This retrospective study included patients with upper urinary tract calculi who received SFUI in our hospital between July 2020 and August 2021. All patients underwent a diagnosis of medical history, and routine preoperative examinations including urine tests, urine culture, hematology tests, kidney function tests, and kidney imaging. Patients with indications were included. No exclusion criteria. The study was reviewed and approved by the Institutional Review Board, and informed consent was waived.

Upper urinary tract stone complexity was scored by Guy’s scoring system [11]: grade 1, solitary stone in mid/lower pole or pelvis with simple anatomy; grade 2, solitary stone in the upper pole or multiple stones with simple anatomy, or a solitary stone with abnormal anatomy; grade 3, multiple stones with abnormal anatomy or stones in a calyceal diverticulum or partial stag horn calculus; grade IV, stag horn calculus or any stone with spina bifida or spinal.

**Surgery**
The SFUI system contained a patented irrigation and suctioning platform and ureteral access sheath (UAS) as previously described (Fig. 1A, B) [12–14]. This system can precisely regulate the infusion flow and control the vacuum suctioning through computerized real-time recording. UAS, in which pressure sensor is located at the front end (Fig. 1B), was placed at the proximal ureter. Renal pelvic pressure was monitored by UAS and the value was shown on the system in the frequency of 6 Hz.

All surgeries were performed by one surgeon with a real-time monitor of renal pelvic pressure during the surgery. The whole flexible ureteroscopic lithotripsy procedure was performed under general anesthesia in oblique supine lithotomy position with the diseased side upward (Fig. 1C). Initial ureteroscopy was performed with a semi-rigid 8/9.8 F ureteroscope (Richard Wolf, Germany), during which a flexible 0.032-inch guidewire (Innovel, China) was inserted into the renal collecting system. Next, the patented UAS was inserted into the proximal ureter along the guidewire without fluoroscopic guidance. A disposable flexible ureteroscope (Pusen, China) was then inserted into the sheath to do a comprehensive inspection of the delivery location of the transparent sheath between mucosa of renal pelvis and ureter. After confirming that the transparent sheath is on the target position, the pressure sensory and suctioning channels were connected to the irrigation and suctioning platform. After being injected with water, zero calibration was carried out for the pressure sensory system. Fully automatic mode of the platform was then selected. Perfusion flow was set at 50-150ml/min. Renal pelvic pressure control value was set at -15–5mmHg. The maximum (limit) value was set at 30 mmHg. Intraoperatively, a holmium laser (Raykeen, China) was used to pulverize the stone at 0.8-1.6 J/pulse with a frequency of 20–30 pulses/s. In the process of lithotripsy, the scope body was moved back and forth slightly in an uninterrupted fashion in the sheath to...
facilitate the small gravel particles inside the sheath gap to be sucked out. Gravel particles larger than sheath gap but less than UAS in diameter were sucked out by withdrawing the scope intermittently without a need of stone basketing. For distal or mid-ureter stone, semi-rigid ureterscope was used. For patients whom the UAS was not indwelled successfully, a 7 F Double-J ureteral stent (Asymchem Inc., China) was indwelled for 2 weeks to facilitate the UAS placement for flexible ureteroscopy.

Vital signs were monitored and laboratory examinations were checked postoperatively including complete blood count, electrolytes, and calcitonin. Because repeated suction of enormous stone fragments could hurt the mucosa of ureter, a 7 F double-J ureteral stent with outer diameter F14.8 was placed at the end of the procedure and was indwelled for 4 weeks to protect the ureter, reducing the occurrence of postoperative complications such as ureter stenosis. Patients were followed at 4th week postoperatively.

Outcome indicators
The primary outcome was stone free rate (SFR), defined as no residual stone or residual stone < 4 mm in size by X-ray image at one session and at one month after surgery, respectively. According to the Chinese Guideline for Diagnosis of Urology and Male Diseases 2019, intense follow-up is allowed for residual stone ≤4 mm without obstruction or infection. The secondary outcome was complications classified by Clavien-Dindo grade: grade 1, any deviation from normal postoperative course without need for pharmacological treatment, except antiemetics, antipyretics, analgetics, diuretics, electrolytes, and calcitonin. Because repeated suction of enormous stone fragments could hurt the mucosa of ureter, a 7 F double-J ureteral stent with outer diameter F14.8 was placed at the end of the procedure and was indwelled for 4 weeks to protect the ureter, reducing the occurrence of postoperative complications such as ureter stenosis. Patients were followed at 4th week postoperatively.

Statistical analysis
Continuous data without normal distribution are presented as median (interquartile) and performed by Wilcoxon rank. Categorical data are presented as n (%) and performed by the Chi-squared test or Fisher’s exact test, as appropriate. Multiple logistic regression was adjusted for the covariates with a p-value < 0.1 in the univariate analysis. Data are presented as odds ratio (OR) and 95% confidence interval (CI). All p values are two-sided, and p-value < 0.05 is considered statistically significant. All statistical analyses were performed using the statistical software package SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

Result
A total of 278 patients were enrolled, including 310 kidneys undergoing SFUI. The baseline characteristics are presented in Table 1. The median age was 50 years (interquartile 40–59 years), with a majority of males (63.55%), median BMI of 24.8 (22.86–26.99), and 105 patients had a stone history (33.87%). The median surgery time was 75 min (60–110 min). Most patients had multiple stones (54.19%), with 75.81% stone < 30 mm, 66.13% of complex composition, 38.71% hydronephrosis Grade I and 33.87% Grade II (38.71% and 33.87%). There were 54.52% patients with Guy’s stone score of Grade I, and stone were mostly located in the ureter (46.77%) and lower segment (45.48%). The clinical outcomes are shown in Table 2. Among 310 kidneys, one session SFR and one-month SFR were 80.65% and 82.26%. Only 8 patients had Clavien-Dindo Grade II, and 2 patients had Grade III complications (ureter lesions). Twelve patients (3.87%) underwent a second stage procedure and 3 patients (0.97%) underwent third stage procedure.

Multiple logistic regression analysis of one-session SFR is shown in Table 3. Patients with stone history (Yes: 69.52% vs. no: 86.34%, p < 0.001 (multiple: 69.64% vs. single: 93.66%, p < 0.001), stone size ≥ 40 mm (≥ 40 mm: 41.18–45.45% vs. < 40 mm: 72.22–91.55%, p < 0.001), and Guy’s stone score ≥ 3 (≥ 3: 40.0–42.86% vs. < 3: 71.05–93.49%, p < 0.001) had significantly lower chance to reach stone free in one session. Patients with one-session stone-free had less surgery time (75 vs. 99 min, p < 0.001). After adjusting the related variables, stone history (adjusted OR (aOR): 2.39, 95% CI: 1.21–4.73), large stone size (≥49 mm: aOR = 4.37, 95% CI = 1.16–16.45, compared to stone < 20 mm), and high Guy’s stone score (Grade II: aOR = 10.95, 95% CI: 2.65–45.25; Grade II: aOR = 3.54, 95% CI: 1.18–10.59, compared to Grade I respectively) still displayed significantly higher risks of not completely cleaned stone in one session.

Multiple logistic regression analysis of one-month SFR is shown in Table 4. The results of one-month SFR were similar with one-session SFR. After adjusting the related variables, stone history (aOR: 2.48, 95% CI: 1.24–4.97) and Guy’s stone score (Grade II: aOR: 4.44, 95% CI: 1.35–14.58; Grade III, aOR: 15.44, 95% CI: 3.48–68.55, compared to Grade I respectively) displayed significantly higher risks of not completely cleaned stone in one-month after SUFI. Besides, although there was no significant association between hydronephrosis and one session or one-month SFR, SFR was reduced as the hydronephrosis grade elevated.

Multiple logistic regression analysis of complication classified by Clavien-Dindo grade is shown in Table 5. Patients with multiple stone number (5.95% vs. single: 0%, p = 0.002), big stone size (≥ 50 mm: 13.64% vs. other
size: 1.08–5.88%, $p = 0.028$), and higher Guy’s stone score (Grade I to VI: 0.59–14.29%, $p = 0.002$) had higher proportion to reach Grade II-IV. After adjusting for the stone size, Guy’s stone score remained significantly correlated to complications (Grade III vs. Grade I: aOR = 22.36, 95% CI = 1.81-276.36).

Table 6 lists the one-session SFR in Guy’s stone score grade and stone size category. One-session SFR was higher than 87% in Guy’s stone score Grade I among all included stone sizes. However, one-session SFR was less than 80% when Guy’s stone score Grade I among all included stone sizes. Therefore, SFUI has a potential to be an

Discussion
This study demonstrated good safety and efficacy of SFUI, with one-session SFR of 80.65% (250/310) and a low complication rate (3.26%). Patients with stone size < 40 mm or Guy’s stone score of Grade I had a significantly higher potential to reach stone-free after SFUI treatment. The unique advantage of SFUI is to clear renal stone with real-time monitoring RPP and increased perfusion flow to kidney safely, solving the very gap of moving out pulverized stone under FURL treatment. It surmounts the limitation of clearing kidney stone > 20 mm through urinary tract and displays high one-session SFR with rare complications. Therefore, SFUI has a potential to be an
Table 3 The comparison of one session stone free rate (SFR) and estimated OR for non-one session stone free

| Variables                        | One session stone free | p-value | Multivariate analysis | aOR (95% CI) |
|----------------------------------|------------------------|---------|-----------------------|--------------|
|                                  | Yes (n = 250)          |         |                       |              |
|                                  | No (n = 60)            |         |                       |              |
| **Demography**                   |                        |         |                       |              |
| Age                              | 50 (42.00–59.00)       | 46.5 (35.50–58.00) | 0.176 | – |
| Gender                           | 0.525                  | – |                       |              |
| Male                             | 161 (81.73)            | 36 (18.27) | – | \textendash |
| Female                           | 89 (78.76)             | 24 (21.24) | 0.634 | – |
| BMI                              | 24.81 (22.86–26.99)    | 24.42 (22.90–26.93) | 0.320 | – |
| Stent in ureter                  | 0.320                  | – |                       |              |
| Yes                              | 47 (85.45)             | 8 (14.55) | – | \textendash |
| No                               | 203 (79.61)            | 52 (20.39) | 0.105 | – |
| Infection                        | 0.105                  | – |                       |              |
| Yes                              | 188 (78.66)            | 51 (21.34) | – | \textendash |
| No                               | 62 (87.32)             | 9 (12.68) | 0.634 | – |
| **Disease history**              |                        |         |                       |              |
| Stone                            | < 0.001                | 2.39 (1.21, 4.73) | – | \textendash |
| Yes                              | 73 (69.52)             | 32 (30.48) | – | \textendash |
| No                               | 177 (86.34)            | 28 (13.66) | 0.770a | – |
| Other kidney diseases            | 0.770a                 | – |                       |              |
| Yes                              | 15 (78.95)             | 4 (21.05) | – | \textendash |
| No                               | 235 (80.76)            | 56 (19.24) | 0.770a | – |
| DM                               | 0.363                  | – |                       |              |
| Yes                              | 41 (85.42)             | 7 (14.58) | – | \textendash |
| No                               | 209 (79.77)            | 53 (20.23) | 0.363 | – |
| Hypertension                     | 0.597                  | – |                       | \textendash |
| Yes                              | 71 (82.56)             | 15 (17.44) | – | \textendash |
| No                               | 179 (79.91)            | 45 (20.09) | 0.597 | – |
| Medicine user and weakness       | 0.847                  | – |                       | \textendash |
| Yes                              | 27 (79.41)             | 7 (20.59) | – | \textendash |
| No                               | 223 (80.8)             | 53 (19.2) | 0.847 | – |
| Operation                        |                        |         |                       |              |
| Operation time                   | < 0.001                | 1.01 (1.00, 1.01) | – | \textendash |
| Yes                              | 75 (60.0–105.0)        | 99 (70.0–144.0) | – | \textendash |
| No                               | 177 (86.34)            | 28 (13.66) | 0.001 | – |
| Stone number                     | < 0.001                | 1.11 (0.34, 3.60) | – | \textendash |
| Single                           | 133 (93.66)            | 9 (6.34) | – | \textendash |
| Multiple                         | 117 (69.64)            | 51 (30.36) | 1 | \textendash |
| Stone size(mm)                   | < 0.001                | 4.37 (1.16, 16.45) | – | \textendash |
| < 20                             | 130 (91.55)            | 12 (8.45) | – | \textendash |
| 20–29                            | 77 (82.80)             | 16 (17.20) | 1.34 (0.54, 3.36) | \textendash |
| 30–39                            | 26 (72.22)             | 10 (27.78) | 1.67 (0.53, 5.26) | \textendash |
| 40–49                            | 7 (41.18)              | 10 (58.82) | 4.37 (1.16, 16.45) | \textendash |
| ≥ 50                             | 10 (45.45)             | 12 (54.55) | 2.41 (0.58, 9.96) | \textendash |
| Composition                      | 0.368                  | – |                       | \textendash |
| Calcium oxalate                  | 55 (78.57)             | 15 (21.43) | – | \textendash |
| Calcium phosphate                | 18 (78.26)             | 5 (21.74) | – | \textendash |
| Uric acid and magnesium ammonium phosphate | 12 (100.00) | 0 (0.00) | – | \textendash |
| Complex                           | 165 (80.49)            | 40 (19.51) | – | \textendash |
| Hydrouphrosis                    | 0.806                  | – |                       | \textendash |
| Grade 0                          | 38 (80.85)             | 9 (19.15) | – | \textendash |
| Grade I                          | 97 (80.83)             | 23 (19.17) | 0.806 | – |
option for patients with large kidney stones for diminished injury and faster recovery.

The present study showed the one-session SFR $\geq 87\%$ among patients with Guy's stone score of Grade I among all included stone sizes, and few postoperative complications of Clavien-Dindo grade $\geq$ Grade II. This suggests that SFUI is optimal for patients with Guy's stone score of Grade I regardless of stone size. It was reported that the SFR with FURL treatment reached $> 95\%$ for stone $\leq 2$ cm [15, 16], but significantly reduced to $\sim 60\%$ for stone $> 2$ cm [14–16] or required more procedures [17, 18]. SFR of FURL reduced as stone size increased. Meta-analysis studies reported that the SFR of PCNL was significantly higher than FURL, while the safety of FURL was higher than PCNL [19, 20]. However, comparative nonrandomized studies of small cohort reported comparable complication rate and comparable SFR of FURL and PCNL for stone $\leq 3$ cm [21, 22], but a significantly higher SFR in PCNL than FURL for stone $> 3$ cm [19]. Compared to FURL and PCNL, SFUI displayed good one-session SFR with rare postoperative complications in all included stone sizes.

Our results showed significantly negative correlation of Guy’s stone score with SFRs and complications. Therefore, Guy’s stone score could be used as a predictive factor of SFR and complications for patients received SFUI. Guy’s stone score is a widely used validated scoring system to provide standardized information of stone complexity and treatment outcomes [23]. There are several scoring systems assessing the complexity of stones, including Guy’s stone score, S.T.O.N.E., and CROES. Each has advantages and disadvantages, and no one is regard as the very golden standard. Studies showed all these systems have comparable ability in predicting stone-free status [23–26]. More studies are needed to clarify clinical factors associated with outcomes in different patient populations.

Preoperative hydronephrosis was reported to affect the outcome of FURS and PCNL [27, 28]. A case-control study with 66 patients revealed that hydronephrosis might significantly affect the SFR of micropercutaneous nephrolithotomy (microperc), a new minimal-invasive technique [27]. Another retrospective study with 164 patients revealed that the success of FURS might decrease as Grade II or a more severe grade of hydronephrosis [28]. In this study, no association between SFR and hydronephrosis was found; however, one-month SFR was reduced following the elevation of hydronephrosis grade. In addition, studies suggested non-contrast CT detected stone density $> 1000$ HU as a significant predictor of stone fragment failure by extracorporeal shock wave lithotripsy [29, 30]. A tendency toward not completely cleaned stone in one session after SFUI for CT $> 1000$ HU was found in our study, implying more therapeutic protocols after SFUI may be needed to clean residual stone fragments in upper urinary tract.

Limitation

There are some limitations in this study. First, this is a retrospective study with the inherent limitation. Second, the lack of a control group or another surgical method might lead to the bias of data interpretation. Third, postoperative KUB may overestimate the true SFR.
Table 4  The comparison of one-month stone free rate (SFR) and estimated OR for non-one-month SFR

| Variables                                | One-month stone free | p-value | Multivariate analysis |
|------------------------------------------|----------------------|---------|-----------------------|
|                                          | Yes (n = 255)        | No (n = 55) |                |
| Demography                               |                      |         |                       |
| Age                                      | 50 (42.00–60.00)     | 45 (35.00–57.00) | 0.086 | 0.99 (0.96, 1.01) |
| Gender                                   |                      |         |                       |
| Male                                     | 162 (82.23)          | 35 (77.77) | 0.988 | – |
| Female                                   | 93 (82.3)            | 20 (77)  | 0.407 | – |
| BMI                                       | 24.82 (22.86–27.06)  | 24.22 (22.30–26.81) | 0.494 | – |
| Stent in ureter                          |                      |         |                       |
| Yes                                      | 47 (85.45)           | 8 (14.55) | 0.098 | – |
| No                                       | 208 (81.57)          | 47 (18.43) | 0.203 | – |
| Infection                                |                      |         |                       |
| Yes                                      | 193 (80.75)          | 46 (19.25) | 0.203 | – |
| No                                       | 62 (87.32)           | 9 (12.68) | 0.203 | – |
| Disease history                          |                      |         |                       |
| Stone                                    | < 0.001              | 2.48 (1.24, 4.97) | 0.756a | – |
| No                                       | 15 (78.95)           | 4 (21.05) | 0.756a | – |
| DM                                       | 240 (82.47)          | 51 (17.53) | 0.533 | – |
| Yes                                      | 41 (85.42)           | 7 (14.58) | 0.533 | – |
| No                                       | 214 (81.68)          | 48 (18.32) | 0.533 | – |
| Hypertension                             |                      |         |                       |
| Yes                                      | 75 (87.21)           | 11 (12.79) | 0.157 | – |
| No                                       | 180 (80.36)          | 44 (19.64) | 0.157 | – |
| Medicine user and weakness               |                      |         |                       |
| Yes                                      | 27 (79.41)           | 7 (20.59) | 0.645 | – |
| No                                       | 228 (82.61)          | 48 (17.39) | 0.645 | – |
| Operation                                |                      |         |                       |
| Operation time                           | 75 (60.0–105.0)      | 100 (65.0–150.0) | 0.002 | 1.01 (1.00, 1.01) |
| Stone number                             | < 0.001              | 1.01 (1.00, 1.01) | 0.992 | – |
| Single                                   | 134 (94.37)          | 8 (5.63) | 1.003 | 1 (0.92, 1.09) |
| Multiple                                 | 121 (72.02)          | 47 (27.98) | 1.003 | 1 (0.92, 1.09) |
| Stone size (mm)                          | < 0.001              | 1.003 | 0.99 (0.28, 3.48) |
| < 20                                     | 130 (91.55)          | 12 (8.45) | 1.003 | 0.99 (0.28, 3.48) |
| 20–29                                    | 80 (86.02)           | 13 (13.98) | 1.003 | 0.99 (0.28, 3.48) |
| 30–39                                    | 26 (72.22)           | 10 (27.78) | 1.003 | 0.99 (0.28, 3.48) |
| 40–49                                    | 8 (47.06)            | 9 (52.94) | 1.003 | 0.99 (0.28, 3.48) |
| ≥ 50                                     | 11 (50.00)           | 11 (50.00) | 1.003 | 0.99 (0.28, 3.48) |
| Composition                              |                      |         |                       |
| Calcium oxalate                          | 58 (82.61)           | 12 (17.44) | 0.467a | – |
| Calcium phosphate                        | 19 (82.61)           | 4 (17.39) | 0.467a | – |
| Uric acid and magnesium ammonium phosphate | 12 (100.00)       | 0 (0.00) | 0.467a | – |
| Complex                                  | 166 (80.98)          | 39 (19.02) | 0.467a | – |
| Hydronephrosis                           |                      |         |                       |
| Grade 0                                  | 39 (82.08)           | 8 (17.02) | 0.955 | – |
| Grade I                                  | 99 (82.50)           | 21 (17.50) | 0.955 | – |
The significance of bold values were $p < 0.05$

SFR stone free rate; aOR adjusted Odds ratio, BMI body mass index, DM diabetes mellitus, CT computer tomography

Continuous data without normal distribution are presented as median (interquartile) and performed by Wilcoxon rank; Categorical data are presented as n (%) and performed by the Chi-squared test or Fisher’s exact test, as appropriate

**Table 4** (continued)

| Variables | One-month stone free | $p$-value | Multivariate analysis |
|-----------|----------------------|-----------|----------------------|
|           | Yes (n = 255) | No (n = 55) | aOR (95%CI) |
| Grade II | 87 (82.86) | 18 (17.14) | – |
| Grade III | 28 (80.00) | 7 (20.00) | – |
| Grade VI | 2 (66.67) | 1 (33.33) | – |
| CT value (ml) | | | 0.144 |
| $\leq$ 1000 | 183 (84.33) | 34 (15.67) | – |
| $>1000$ | 72 (77.42) | 21 (22.58) | – |
| Guy’s stone score | | | $<0.001^a$ |
| Grade I | 160 (94.67) | 9 (5.33) | 1 |
| Grade II | 84 (73.68) | 30 (26.32) | 4.44 (1.35, 14.58) |
| Grade III | 8 (40.00) | 12 (60.00) | 15.44 (3.48, 68.55) |
| Grade VI | 3 (42.86) | 4 (57.14) | 2.93 (0.28, 30.29) |

**Table 5** The comparison of complication (Clavien-Dindo grade) and estimated OR for Grade II-IV.

| Variables | Clavien-Dindo grade | $p$-value | Multivariate analysis |
|-----------|---------------------|-----------|----------------------|
|           | Grade I (n = 300) | Grade II-IV (n = 10) | aOR (95%CI) |
| Demography | | | 0.603 |
| Age | 50 (40.00–59.00) | 44.5 (39.00–58.00) | – |
| Gender | | | 0.179 |
| Male | 193 (97.97) | 4 (2.03) | – |
| Female | 107 (94.69) | 6 (5.31) | – |
| BMI | 24.79 (22.85–26.82) | 26.22 (23.88–27.28) | 0.259 |
| Stent in ureter | | | 1.000$^a$ |
| Yes | 54 (98.18) | 1 (1.82) | – |
| No | 246 (96.47) | 9 (3.53) | – |
| Infection | | | 0.701$^a$ |
| Yes | 232 (97.07) | 7 (2.93) | – |
| No | 68 (95.77) | 3 (4.23) | – |
| Disease history | | | 0.738$^a$ |
| Stone | | | 1.000$^a$ |
| Yes | 101 (96.19) | 4 (3.81) | – |
| No | 199 (97.07) | 6 (2.93) | – |
| Other kidney diseases | | | 0.190$^a$ |
| Yes | 19 (100.00) | 0 (0.00) | – |
| No | 281 (96.56) | 10 (3.44) | – |
| DM | | | 0.110$^a$ |
| Yes | 45 (93.75) | 3 (6.25) | – |
| No | 255 (97.33) | 7 (2.67) | – |
| Hypertension | | | 0.301$^a$ |
| Yes | 81 (94.19) | 5 (5.81) | – |
| No | 219 (97.77) | 5 (2.23) | – |
| Medicine user and weakness | | | 0.001$^a$ |
| Yes | 32 (94.12) | 2 (5.88) | – |
| No | 268 (97.1) | 8 (2.9) | – |
Conclusion
Patients undergoing SFUI showed good stone-free rate and rare complications. One-session SFR is >87% in patients with Guy’s stone score I, while high Guy’s stone score is associated with decreased one-session SFR and complications. Patients with stone size <40 mm or Guy’s stone score of Grade I have a high chance to reach stone free after SFUI treatment.

### Table 5 (continued)

| Variables                  | Clavien-Dindo grade | p-value | Multivariate analysis |
|----------------------------|---------------------|---------|-----------------------|
|                            | Grade I (n = 300)   | Grade II-IV (n = 10) | aOR (95%CI) |
| Operation                 |                     |         |                       |
| Operation time            | 75 (60.0–109.5)     | 82.5 (40.0–185.0)    | 0.768     | –                     |
| Stone number              |                     |         |                       |
| Single                    | 142 (100.00)        | 0 (0.00) | –                     |
| Multiple                  | 158 (94.05)         | 10 (5.95)| –                     |
| Stone size (mm)           |                     |         |                       |
| < 20                      | 139 (97.89)         | 3 (2.11) |                       |
| 20–29                     | 92 (98.92)          | 1 (1.08) | 0.32 (0.03, 3.44)      |
| 30–39                     | 34 (94.44)          | 2 (5.56) | 1.02 (0.15, 7.19)      |
| 40–49                     | 16 (94.12)          | 1 (5.88) | 0.73 (0.06, 8.64)      |
| ≥ 50                      | 19 (86.36)          | 3 (13.64)| 1.75 (0.25, 12.35)     |
| Composition               |                     |         |                       |
| Calcium oxalate           | 67 (95.71)          | 3 (4.29) |                       |
| Calcium phosphate         | 21 (91.30)          | 2 (8.70) | –                     |
| Uric acid and magnesium ammonium phosphate | 12 (100.00) | 0 (0.00) | –                     |
| Complex                   | 200 (97.56)         | 5 (2.44) |                       |
| Hydrourephrosis           |                     |         |                       |
| Grade 0                   | 45 (95.74)          | 2 (4.26) |                       |
| Grade I                   | 115 (95.83)         | 5 (4.17) |                       |
| Grade II                  | 102 (97.14)         | 3 (2.86) |                       |
| Grade III                 | 35 (100.00)         | 0 (0.00) | –                     |
| Grade VI                  | 3 (100.00)          | 0 (0.00) | –                     |
| CT value (ml)             |                     |         |                       |
| ≤ 1000                    | 211 (97.24)         | 6 (2.76) |                       |
| > 1000                    | 89 (95.70)          | 4 (4.30) |                       |
| Guy’s stone score         |                     |         |                       |
| Grade I                   | 168 (99.41)         | 1 (0.59) |                       |
| Grade II                  | 109 (95.61)         | 5 (4.39) | 8.11 (0.79, 82.96)     |
| Grade III                 | 17 (85.00)          | 3 (15.00)| 22.36 (1.81, 276.36)   |
| Grade VI                  | 6 (85.71)           | 1 (14.29)| 15.90 (0.55, 456.26)   |

The significance of bold values were p < 0.05

aOR adjusted Odds ratio, BMI body mass index, DM diabetes mellitus, CT computer tomography
Continuous data without normal distribution are presented as median (interquartile) and performed by Wilcoxon rank; Categorical data are presented as n (%) and performed by the Chi-squared test or *Fisher’s exact test, as appropriate

### Table 6 One session stone free rate (SFR) in Guy’s stone score grade and stone size category

| Stone size (mm) | Guy’s stone score | One session stone free/N (%) |
|-----------------|-------------------|------------------------------|
|                 | Grade I | Grade II | Grade III | Grade IV |
| < 20            | 108/112 (96.43) | 19/24 (79.17) | 3/6 (50.00) | 0/0 (–) |
| 20–29           | 41/47 (87.23) | 35/45 (77.78) | 1/1 (100.00) | 0/0 (–) |
| 30–39           | 7/8 (87.50) | 17/24 (70.83) | 2/4 (50.00) | 0/0 (–) |
| 40–49           | 1/1 (100.00) | 4/10 (40.00) | 1/4 (25.00) | 1/2 (50.00) |
| ≥ 50            | 1/1 (100.00) | 6/11 (54.55) | 1/5 (20.00) | 2/5 (40.00) |

SFR stone free rate
Abbreviations
SFUI: Suctioning flexible ureteroscopy with intelligent pressure-control; SFR: Stone-Free Rate; PCNL: Percutaneous nephrolithotomy; FURL: Flexible ureteroscopy lithotripsy; aOR: Adjusted odds ratio; CI: Confidence interval.

Acknowledgements
None.

Author contributions
XJ Gao, ZD Zhang, YJ Lu: Conception and design; XW Li, WP Cai: Administrative support; B Zheng, YJ Lu: Provision of study materials or patients; HL Zhao, JH You, GF Zheng: Collection and assembly of data; WL Bao, YT Lai, YS Lv: Data analysis and interpretation; Manuscript writing: All authors; Final approval of manuscript: All authors. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
All data analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
This study’s protocol was reviewed and approved by the Internal Review Board of the General Hospital of Fujian Energy Group before this study was conducted (NO.Funjeng2020-59). Ethics committee of the General Hospital of Fujian Energy Group waived the need for informed consent because of the retrospective study design. All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 27 January 2022   Accepted: 20 October 2022
Published online: 10 November 2022

References
1. Dorantes-Carrillo LA, Basulto-Martínez M, Suárez-Ibarrola R, Heinze A, Proetz S, Flores-Tapia JP, et al. Retrograde intrarenal surgery versus miniaturized percutaneous nephrolithotomy for kidney stones > 1 cm: A systematic review and meta-analysis of randomized trials. Eur Urol Focus. 2022;8(1):259–70.
2. Takazawa R, Kitayama S, Tsujii T. Successful outcome of flexible ureteroscopy with holmium laser lithotripsy for renal stones 2 cm or greater. Int J Urol. 2012;19:264–7.
3. Cohen J, Cohen S, Grasso M. Ureteropyeloscopic treatment of large, complex intrarenal and proximal ureteral calculi. BJU Int. 2013;111:127–31.
4. Desai M, Sun Y, Buchholz N, e Dorantes-Carrillo LA, Basulto-Martinez M, Suárez-Ibarrola R, et al. Treatment selection for urolithiasis: percutaneous nephrolithotomy, ureteroscopy, shock wave lithotripsy, and active monitoring. World J Urol. 2017;35:1395–9.
5. Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, et al. Surgical Management of Stones: American Urological Association/ Endourological Society Guideline, PART I. J Urol. 2016;196(4):1153–60.
6. Hung J, Oster H. Intraluminal pressure profiles during flexible ureterorenoscopy. SpringerPlus. 2015;4(1):1–5.
7. Zhong W, Lai S, Wang L, Zeng G. Systemic inflammatory response syndrome after flexible ureteroscopic lithotripsy: a study of risk factors. J Endourol. 2015;29:25–8.
8. de la Rosette J, Dendratis J, Geavlete P, Keeley F, Matsuda T, Pearle M, et al. The clinical research office of the endourological society ureteroscopy global study: indications, complications, and outcomes in 11,885 patients. J Endourol. 2014;28:131–9.
9. Huang J, Xie D, Xiong R, Deng X, Huang C, Fan D, et al. The application of suctioning flexible ureteroscopy with intelligent pressure control in treating upper urinary tract calculus on patients with a solitary kidney. Urology. 2018;111:44–7.
10. Zhu Z, Cui Y, Zeng F, Li Y, Chen Z, Hequn C. Comparison of suctioning and traditional ureteral access sheath during flexible ureteroscopy in the treatment of renal stones. World J Urol. 2019;37(5):921–9.
11. Thomas K, Smith NC, Hegarty N, Jonathan M, Glass JM. The Guy’s stone score—grading the complexity of percutaneous nephrolithotomy procedures. Urology. 2011;78(2):277–81.
12. Deng X, Song L, Xie D, Fan D, Zhu L, Yao L, et al. A novel flexible ureteroscopy with intelligent control of renal pelvis pressure: an initial experience of 93 cases. J Endourol. 2016;30(10):1067–72.
13. Deng X, Song L, Xie D, Huang J, Zhu L, Su G, et al. Suctioning flexible ureteroscopy with automatic control of renal pelvic pressure, a pocrine model. Int J Clin Exp Med. 2016;9(3):5658–8.
14. Zhu X, Song L, Xie D, Peng Z, Guo S, Deng X, et al. Animal experimental study to test application of intelligent pressure control device in monitoring and control of renal pelvic pressure during flexible ureteroscopy. Urology. 2016;91:242.e11–242.e2.42E15.
15. Lee JW, Park J, Lee SB, Son H, Cho SY, Jeong H. Mini-percutaneous Nephrolithotomy vs retrograde Intrarenal surgery for renal stones larger than 10 mm: a prospective randomized controlled trial. Urology. 2015;86(5):873–7.
16. Hussain M, Acher P, Penve B, Cynk M. Redefining the limits of flexible ureterorenoscopy. J Endourol. 2011;25:45–9.
17. Scotland KB, Rudnick B, Healy KA, Hubosky SG, Bagley DH. Retrograde ureteroscopy management of large renal calculi: a single institutional experience and concise literature review. J Endourol. 2018;32:603–7.
18. Chen HQ, Chen ZY, Zeng F, Li Y, Yang ZQ, He C, et al. Comparative study of the treatment of 20–30 mm renal stones with miniaturized percutaneous nephrolithotomy and flexible ureterorenoscopy in obese patients. World J Urol. 2018;36:1309–14.
19. Kang SK, Cho KS, Kang DH, Jung HD, Kwon JK, Lee JY. Systematic review and meta-analysis to compare success rates of retrograde intrarenal surgery versus percutaneous nephrolithotomy for renal stones > 2 cm. Med (Baltim). 2017;96:e9119.
20. Chen Y, Wen Y, Yu Q, Duan X, Wu W, Zeng G. Percutaneous nephrolithotomy versus flexible ureteroscopic lithotripsy in the treatment of upper urinary tract stones: a meta-analysis comparing clinical efficacy and safety. BMC Urol. 2020;20:109.
21. Rao P, Li J, Shen S, Zhao H. A research on flexible ureteroscope lithotripsy versus percutaneous nephrolithotomy for upper urinary tract calculi. Int J Clin Exp Med. 2020;13:1115–22.
22. Pieras E, Tubau V, Brugarolas X, Ferrutxe J, Piza P. Comparative analysis between percutaneous nephrolithotomy and flexible ureteroscopy in kidney stones of 2–3 cm. Actas Urol Esp. 2017;41:194–9.
23. Wu WJ, Okeke Z. Current clinical scoring systems of percutaneous nephrolithotomy outcomes. Nat Rev Urol. 2017;14:459–69.
24. Kang J, Sun F, Zhu J, Luo G, Zhang P, Ban Y, et al. Evaluation of three stone-scoring systems for predicting SFR and complications after percutaneous nephrolithotomy: a systematic review and meta-analysis. BMC Urol. 2019;19(1):57.
25. Khan N, Nazim SM, Farhan M, Salam B, Ather MH. Validation of S.T.O.N.E nephrolithometry and Guy’s stone score for predicting surgical outcome after percutaneous nephrolithotomy. Urol Ann. 2020;12(4):324–30.
26. Lai S, Jiao B, Jiang Z, Liu J, Seery S, Chen X, et al. Comparing different kidney stone scoring systems for predicting percutaneous nephrolithotomy outcomes: A multicenter retrospective cohort study. Int J Surg. 2020;81:55–60.
27. Kadihasanoglu M, Erkan E, Yucetas U, Gokhan Culha M, Gokhan Toktas M, Atahan O. Does preoperative hydronephrosis affect the stone-free rate of micro-percutaneous nephrolithotomy? Arch Esp Urol. 2019;72(4):406–14.
28. Ergani B, Ozbilgen MH, Yalcin MY, Boyacoglu H, Ilbey YO. The effect of hydroureteronephrosis grade on stone-free rate in retrograde intrarenal stone surgery with flexible ureterorenoscopy. Am J Clin Exp Urol. 2021;9(2):194–201.
29. Abdelhamid M, Mosharafa AA, Ibrahim H, Selim HM, Hamed M, Elghoneimy MN, et al. A prospective evaluation of high-resolution CT parameters in predicting extracorporeal shockwave lithotripsy success for upper urinary tract calculi. J Endourol. 2016;30(11):1227–32.

30. El-Nahas AR, El-Assmy AM, Mansour O, Sheir KZ. A prospective multivariate analysis of factors predicting stone disintegration by extracorporeal shock wave lithotripsy: the value of high-resolution noncontrast computed tomography. Eur Urol. 2007;51(6):1688–93. discussion 1693-4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.